Look AHEAD

Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes

Top

Exclusive! Expert diabetes blog post from Silvio E. Inzucchi, MD. Espeland MA, Glick HA, Bertoni A, et al; for the Look AHEAD Research Group. Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: The Action for Health in Diabetes. Diabetes Care. 2014;37:2548-2566.

Four-year weight losses in the Look AHEAD study: factors associated with long-term success

Top

Alert: October 20, 2012: The Look AHEAD trial has been halted due to futility. Read exclusive commentary from Anne Peters, MD, one of the study’s principal investigators, on the important role of lifestyle interventions for preventing obesity and diabetes despite the lack of CV benefit seen in the trial. Wadden TA, Neiberg RH, Wing RR, et al; for the Look AHEAD Research Group. Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity. 2011;19(10):1987-1998. This analysis of 4-year data from the Look AHEAD (Action for Health in Diabetes) trial examined the effect of lifestyle on weight loss and identified demographic characteristics and lifestyle behaviors associated with sustained weight loss in the intensive lifestyle intervention treatment group.

Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial

Top

Unick JL, Beavers D, Jakicic JM, et al; for the Look AHEAD Research Group. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes. Diabetes Care. 2011;34(10):2152-2157. This study by Unick and colleagues examined 1-year results from the Action for Health in Diabetes (Look AHEAD) trial, which assessed weight loss, changes in cardiovascular disease risk factors, and compliance with diet and fitness recommendations among overweight/obese subjects stratified by body mass index (BMI).

Evaluating the long-term cost-effectiveness of liraglutide vs exenatide BID in patients w/ type 2 diabetes who fail to improve w/ oral antidiabetic agents

Top

Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clin Ther. 2011 Oct 19. [Epub ahead of print] The global clinical and economic burden of type 2 diabetes is substantial. Recently, clinical trials with glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide and exenatide) have shown a multifactorial clinical profile with the potential to address many of the clinical needs of patients and reduce the burden of disease.

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

Top

Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L; the Look AHEAD Research Group. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes. Diabetes Care. 2011;34(7):1481-1486. Overweight and obese individuals are encouraged to lose 5-10% of their body weight to improve cardiovascular disease (CVD) risk, but data supporting this recommendation are limited, particularly for individuals with type 2 diabetes.

Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD)

Top

McEwen LN, Bilik D, Johnson SL, et al. Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD). ACC Abstracts of the 48th Scientific Session. 2009;32(6):971-976. The purpose of this study was to examine the predictors of intensification of antihyperglycemic therapy in patients with type 2 diabetes; its impact on A1C, body weight, symptoms of anxiety/depression, and health status; and patient characteristics associated with improvement in A1C.

Effects of Pioglitazone Versus Diet and Exercise on Metabolic Health and Fat Distribution in Upper Body Obesity

Top

Shadid S, Jensen MD. Effects of Pioglitazone Versus Diet and Exercise on Metabolic Health and Fat Distribution in Upper Body Obesity. Diabetes Care. 2003;26:3148-3152. Insulin resistance is associated with visceral adiposity, and interventions that reduce this depot, e.g., diet and exercise, improve insulin resistance. Thiazolidinediones (TZDs) also improve insulin action but paradoxically increase total fat mass, perhaps through remodeling (recruitment of smaller fat cells) and redistribution of adipose tissue.

Peroxisome Proliferator–Activated Receptor-a Agonist Treatment in Transgenic Model of Type 2 Diabetes Reverses Lipotoxic State & Improves Glucose Homeostasis

Top

Kim H, Haluzik M, Asghar Z, et al. Peroxisome Proliferator-Activated Receptor-alpha Agonist Treatment in a Transgenic Model of Type 2 Diabetes Reverses the Lipotoxic State and Improves Glucose Homeostasis. Diabetes. 2003;52:1770-1778. Abnormalities in insulin action are the characteristics of type 2 diabetes. Dominant-negative muscle-specific IGF-I receptor (MKR) mice exhibit elevated lipid levels at an early age and eventually develop type 2 diabetes.

High White Blood Cell Count Is Associated With a Worsening of Insulin Sensitivity and Predicts the Development of Type 2 Diabetes

Top

Vozarova B, Weyer C, Lindsay RS, et al. High White Blood Cell Count Is Associated With a Worsening of Insulin Sensitivity and Predicts the Development of Type 2 Diabetes. Diabetes. 2002;51:455-461. Chronic low-grade inflammation may be involved in the pathogenesis of insulin resistance and type 2 diabetes. We examined whether a high white blood cell count (WBC), a marker of inflammation, predicts a worsening of insulin action, insulin secretory function, and the development of type 2 diabetes in Pima Indians.